Is dual non-responsiveness to antiplatelet treatment a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin?
Dual low responsiveness to clopidogrel and aspirin is a strong predictor of cardiac adverse events, especially in patients with diabetes mellitus, which underlines the need for personalized antiplatelet treatment.
Victorian GPN involved in the Australian Primary Care Collaborative appear more 'ready' than GPN without this experience to undertake clinical data management for reporting purposes on the national performance indicators under the NQPS.